PharmaBioSource was born when our founder and CEO, William (Bill) Wiederseim was engaged to divest several pharmaceutical manufacturing sites for a multinational pharmaceutical company.
In addition to the need for engineering expertise to understand the technical aspects of manufacturing facilities and equipment, a global real estate and a financial consulting firm were also engaged by the client to be part of the consolidation team. When the client expressed how much quicker and more efficient the divestment of multiple manufacturing sites could be, were there a single company who understood the manufacturing of pharmaceutical products, the financials and accounting involved with running a manufacturing operation and the ability to execute site and facility divestments, Bill ran with the idea. He went out and put together a team of Pharma industry executives, engineers, scientists, finance and manufacturing operations experts with years of industry experience. Bringing them all together, Bill launched PharmaBioSource, a specialized single entity that could spearhead biopharma asset transactions from conception to close.
From those humble beginnings over 20 years ago, we have grown to a multinational team with a presence on three continents, over 100+ transactions in therapeutic assets and pharmaceutical facilities with a value of over US $5 Billion. PharmaBioSource was created to solve problems, and that is still our expertise today.
“You need the right team in a field as specialized, complex, and challenging as ours. Our people are among the best in their respective areas of expertise, and we make sure we provide an environment in which they can excel. We harness the knowledge and experience of our global team of experts to help our clients successfully transact in the life sciences.”– Bill Wiederseim, CEO
For more than two decades, we have guided leading global biopharmaceutical companies, service providers, and investors with actionable intelligence, innovative strategies, and solutions to transact on life science businesses, pharmaceutical facilities, and therapeutic assets worldwide.